Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$129.37 0.0%	$131.44	$109.76 ▼ $141.23	$225.22B	0.7	7.87 million shs	9.69 million shs
AZN AstraZeneca	$78.47 +0.7%	$72.19	$61.24 ▼ $87.68	$241.72B	0.36	5.48 million shs	5.64 million shs
BMY Bristol Myers Squibb	$47.86 +0.0%	$47.23	$42.96 ▼ $63.33	$97.40B	0.36	13.07 million shs	9.41 million shs
NVS Novartis	$122.24 +0.9%	$118.54	$96.06 ▼ $124.83	$256.03B	0.62	2.05 million shs	1.21 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	-1.17%	-1.24%	-2.01%	-3.00%	+19.54%
AZN AstraZeneca	+3.45%	+5.90%	+8.64%	+14.69%	-6.51%
BMY Bristol Myers Squibb	+2.86%	+6.68%	+0.97%	+4.59%	-2.59%
NVS Novartis	+1.62%	+6.80%	+0.17%	+11.90%	+7.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9922 of 5 stars	3.5	4.0	4.2	4.5	4.1	2.5	2.5
AZN AstraZeneca	2.5888 of 5 stars	1.4	5.0	2.5	0.0	4.1	0.0	1.3
BMY Bristol Myers Squibb	4.7804 of 5 stars	2.1	5.0	4.2	4.0	3.5	2.5	1.3
NVS Novartis	1.7216 of 5 stars	1.0	3.0	2.5	0.0	2.9	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.91	Moderate Buy	$144.47	11.68% Upside
AZN AstraZeneca	2.80	Moderate Buy	$86.00	9.60% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	17.78% Upside
NVS Novartis	2.09	Hold	$123.50	1.03% Upside

Current Analyst Ratings Breakdown

Latest NVS, AZN, ABT, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NVS Novartis	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$123.00
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/1/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $47.00
7/31/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/18/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$147.00 ➝ $142.00
7/18/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$142.00 ➝ $141.00
7/18/2025	ABT Abbott Laboratories	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$148.00 ➝ $145.00
7/18/2025	ABT Abbott Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$143.00 ➝ $145.00
7/17/2025	ABT Abbott Laboratories	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	ABT Abbott Laboratories	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$130.00 ➝ $140.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.37	$6.58 per share	19.66	$29.20 per share	4.43
AZN AstraZeneca	$54.07B	4.50	$6.34 per share	12.38	$14.45 per share	5.43
BMY Bristol Myers Squibb	$48.30B	2.02	$5.89 per share	8.13	$8.59 per share	5.57
NVS Novartis	$50.32B	5.13	$10.79 per share	11.33	$19.91 per share	6.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.21	22.58	2.45	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.66	29.50	15.69	1.44	14.68%	32.84%	12.87%	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.30	7.86	2.45	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	17.79	13.88	1.70	25.64%	41.08%	16.83%	N/A

Latest NVS, AZN, ABT, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.82%	N/A	29.57%	54 Years
AZN AstraZeneca	$1.01	1.29%	N/A	37.97%	N/A
BMY Bristol Myers Squibb	$2.48	5.18%	N/A	100.00%	17 Years
NVS Novartis	$2.60	2.13%	N/A	37.85%	N/A

Latest NVS, AZN, ABT, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
AZN AstraZeneca	0.55	0.86	0.67
BMY Bristol Myers Squibb	2.54	1.21	1.11
NVS Novartis	0.53	0.82	0.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
BMY Bristol Myers Squibb	76.41%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
BMY Bristol Myers Squibb	0.09%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable

NVS, AZN, ABT, and BMY Headlines

Recent News About These Companies

Mondrian Investment Partners LTD Lowers Position in Novartis AG (NYSE:NVS)

August 14 at 6:16 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Purchased by Citigroup Inc.

August 14 at 4:16 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by Callan Family Office LLC

August 13 at 6:37 AM | marketbeat.com

Frank Rimerman Advisors LLC Purchases Shares of 2,711 Novartis AG (NYSE:NVS)

August 13 at 4:37 AM | marketbeat.com

XTX Topco Ltd Sells 8,098 Shares of Novartis AG (NYSE:NVS)

August 13 at 3:14 AM | marketbeat.com

Novartis ianalumab Phase III trial meets primary endpoint in ITP

August 12 at 6:19 PM | msn.com

Todd Asset Management LLC Purchases 5,329 Shares of Novartis AG (NYSE:NVS)

August 12 at 7:53 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

August 12 at 5:19 AM | marketbeat.com

Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial

August 12 at 5:10 AM | finance.yahoo.com

Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial

August 12 at 5:10 AM | msn.com

Novartis AG: Balancing Promising Drug Developments with Market Challenges – Hold Recommendation

August 12 at 4:31 AM | tipranks.com

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

August 12 at 2:15 AM | globenewswire.com

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

August 11 at 2:08 PM | msn.com

AlphaCore Capital LLC Purchases New Stake in Novartis AG (NYSE:NVS)

August 11 at 6:21 AM | marketbeat.com

August 11 at 2:31 AM | gurufocus.com

Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease

August 11 at 2:43 AM | wsj.com

Brokerages Set Novartis AG (NYSE:NVS) PT at $123.50

August 11 at 2:42 AM | americanbankingnews.com

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

August 11 at 2:20 AM | prnewswire.com

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

August 11 at 2:15 AM | globenewswire.com

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

August 10, 2025 | theglobeandmail.com

Novartis AG (NYSE:NVS) Stake Reduced by Atria Wealth Solutions Inc.

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVS, AZN, ABT, and BMY Company Descriptions

Abbott Laboratories NYSE:ABT

$129.37 -0.03 (-0.03%)

Closing price 03:59 PM Eastern

Extended Trading

$129.02 -0.34 (-0.27%)

As of 07:56 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$78.47 +0.53 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$77.61 -0.86 (-1.10%)

As of 07:55 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol Myers Squibb NYSE:BMY

$47.86 +0.01 (+0.03%)

Closing price 03:59 PM Eastern

Extended Trading

$47.86 -0.01 (-0.02%)

As of 07:53 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Novartis NYSE:NVS

$122.24 +1.04 (+0.86%)

Closing price 03:59 PM Eastern

Extended Trading

$119.15 -3.09 (-2.53%)

As of 07:57 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time